Insulet Corporation $PODD Shares Purchased by Stephens Investment Management Group LLC

Stephens Investment Management Group LLC lifted its position in Insulet Corporation (NASDAQ:PODD) by 5.2% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 140,823 shares of the medical instruments supplier’s stock after purchasing an additional 6,971 shares during the quarter. Stephens Investment Management Group LLC owned approximately 0.20% of Insulet worth $43,476,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in PODD. Norges Bank acquired a new position in shares of Insulet in the 2nd quarter valued at $324,689,000. Qube Research & Technologies Ltd purchased a new position in Insulet during the 2nd quarter worth $131,439,000. Worldquant Millennium Advisors LLC purchased a new position in Insulet during the 2nd quarter worth $80,082,000. Munro Partners raised its stake in Insulet by 1,483.0% during the 3rd quarter. Munro Partners now owns 227,240 shares of the medical instruments supplier’s stock valued at $70,156,000 after acquiring an additional 212,885 shares during the last quarter. Finally, AustralianSuper Pty Ltd grew its stake in shares of Insulet by 487.5% in the 2nd quarter. AustralianSuper Pty Ltd now owns 205,168 shares of the medical instruments supplier’s stock valued at $64,460,000 after purchasing an additional 170,247 shares during the last quarter.

Analyst Ratings Changes

A number of brokerages have recently issued reports on PODD. Stifel Nicolaus initiated coverage on shares of Insulet in a research note on Tuesday, October 21st. They set a “buy” rating and a $370.00 price target on the stock. Royal Bank Of Canada increased their target price on Insulet from $370.00 to $380.00 and gave the stock an “outperform” rating in a research note on Friday, November 21st. Evercore ISI started coverage on Insulet in a research note on Tuesday, December 16th. They issued an “outperform” rating and a $370.00 price target on the stock. Truist Financial cut their price objective on Insulet from $412.00 to $390.00 and set a “buy” rating for the company in a research report on Thursday, December 18th. Finally, Raymond James Financial raised their target price on Insulet from $366.00 to $385.00 and gave the company an “outperform” rating in a report on Friday, November 21st. Twenty-one research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, Insulet has a consensus rating of “Moderate Buy” and an average price target of $379.10.

Insulet Stock Performance

Shares of PODD opened at $287.70 on Friday. Insulet Corporation has a 12-month low of $230.05 and a 12-month high of $354.88. The stock has a market cap of $20.24 billion, a P/E ratio of 83.39, a PEG ratio of 1.60 and a beta of 1.40. The company has a current ratio of 2.87, a quick ratio of 2.18 and a debt-to-equity ratio of 0.68. The company has a 50-day moving average of $303.29 and a two-hundred day moving average of $310.82.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. Insulet had a return on equity of 24.36% and a net margin of 9.76%.The firm had revenue of $521.70 million for the quarter, compared to analysts’ expectations of $678.70 million. During the same quarter in the prior year, the firm earned $1.08 EPS. Insulet’s quarterly revenue was up 29.9% on a year-over-year basis. As a group, research analysts predict that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.